Abdominal Neoplasm Clinical Trial
Official title:
KeyScope: First-In-Human Clinical Study for Cancer Diagnosis in Uganda
KeyScope and KeyLoop (collectively called KeySuite) are laparoscopic prototypes that the investigators have designed for the resources, needs and challenges of low- and middle- income countries (LMICs). KeyScope is a laparoscope that plugs into a laptop computer to display images during surgery. It links to a telementoring application so that experienced surgeons can mentor surgeons in capacity-building partnerships. KeyLoop is a laparoscopic retractor that lifts the abdominal wall during surgery, obviating the need for a constant power supply and medical-grade carbon dioxide. The investigators will perform a clinical First-in-Human study at the Uganda Cancer Institute. Ugandan surgeons will use the KeySuite devices to perform biopsies of intra-abdominal tumors.
Status | Not yet recruiting |
Enrollment | 12 |
Est. completion date | September 30, 2026 |
Est. primary completion date | September 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - diagnosis of intra-abdominal mass suspicious for cancer - body mass index (BMI) of 18-30 - weight 20-100kg - biopsy necessary to determine cancer diagnosis and classify pathology - surgeon determine that laproscopic biopsy it technically appropriate Exclusion Criteria: - significant comorbidities - previous major abdominal surgery - current pregnancy |
Country | Name | City | State |
---|---|---|---|
Uganda | Uganda Cancer Institute | Kampala |
Lead Sponsor | Collaborator |
---|---|
Duke University | Makerere University, Uganda Cancer Institute |
Uganda,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Surgical site infection | Any infections at the surgical site will be recorded and followed until resolution | 30 days | |
Other | Post-operative complications | All post-operative complications will be recorded | 30 days | |
Other | Mortality | Survival through 30 days | 30 days | |
Primary | Establish the clinical safety KeySuite | This will be determined by whether or not the procedure was able to be completed laproscopically or had to be converted to open surgery. | Day of surgery | |
Secondary | Time to complete surgery | Length of surgery will be recorded | Day of surgery | |
Secondary | Estimated blood loss | Blood loss will be recorded | Day of surgery | |
Secondary | Surgical injuries and adverse events | Surgical injuries (device-related and unrelated) and other adverse events at the time of surgery will be recorded | Day of surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05617755 -
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
|
Phase 1 | |
Completed |
NCT03513757 -
Dexmedetomidine and Propofol for Pediatric MRI Sedation
|
Phase 4 | |
Recruiting |
NCT05308771 -
To Investigate the Use of a New Syringe "Visual Pressure Control (VPC)" for Epidural Anesthesia in Children Surgery
|
N/A | |
Not yet recruiting |
NCT06276738 -
The LINFU® U.S. Registry in Patients With Clinical Signs and/or Symptoms of Disease
|
||
Completed |
NCT03890640 -
Ultrasound-assisted Thoracic Epidural Catheter Insertion
|
N/A | |
Recruiting |
NCT03150992 -
EDMONd - Elemental Diet in Bowel Obstruction
|
N/A | |
Recruiting |
NCT05592626 -
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00004547 -
Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy
|
Phase 2 | |
Recruiting |
NCT06042023 -
Remote Patient Monitoring for Preoperative Risk Assessment
|
N/A | |
Recruiting |
NCT01894828 -
Nutritional Supplementation in Patients With no Signs of Malnutrition
|
Phase 4 |